INNOHEP Drug Patent Profile
✉ Email this page to a colleague
When do Innohep patents expire, and what generic alternatives are available?
Innohep is a drug marketed by Leo Pharma As and is included in one NDA.
The generic ingredient in INNOHEP is tinzaparin sodium. There is one drug master file entry for this compound. Additional details are available on the tinzaparin sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INNOHEP?
- What are the global sales for INNOHEP?
- What is Average Wholesale Price for INNOHEP?
Summary for INNOHEP
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 20 |
| Patent Applications: | 1,008 |
| DailyMed Link: | INNOHEP at DailyMed |
Recent Clinical Trials for INNOHEP
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Galician Research Group on Digestive Tumors | Phase 3 |
| Region Jönköping County | Phase 2 |
| University Hospital, Linkoeping | Phase 2 |
US Patents and Regulatory Information for INNOHEP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Pharma As | INNOHEP | tinzaparin sodium | INJECTABLE;INJECTION | 020484-001 | Jul 14, 2000 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
